KRYS实时信号 | 通过Getagraph.com最大化利润

出售 5385 min ago

@ $156.83

发出时间: 26 Apr 2024 @ 01:04

回报率: 0.03%

上一信号: Apr 24 - 03:53

上一信号: 购买

回报率: -3.12 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States...

Stats
今日成交量	165 898
平均成交量	392 008
市值	4.44B
EPS	$0 ( 2024-02-26 )
下一个收益日期	( $0.280 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	402.26
ATR14	$3.80 (2.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	Krishnan Suma	Sell	2 146	Common Stock
2024-03-11	Krishnan Suma	Sell	2 254	Common Stock
2024-03-11	Krishnan Suma	Sell	5 109	Common Stock
2024-03-11	Krishnan Suma	Sell	8 002	Common Stock
2024-03-11	Krishnan Suma	Sell	2 816	Common Stock

INSIDER POWER
4.49
Last 100 transactions
Buy: 214 300 \| Sell: 194 377

音量相关性

長: 0.84 (strong)

短: 0.06 (neutral)

Signal:(45) Neutral

Krystal Biotech Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Krystal Biotech Inc 相关性 - 货币/商品

-0.34
( neutral )

0.42
( neutral )

0.00
( neutral )

-0.05
( neutral )

-0.16
( neutral )

0.30
( neutral )

Krystal Biotech Inc 财务报表

Annual	2023
营收:	$50.70M
毛利润:	$42.60M (84.02 %)
EPS:	$0.400

FY	2023
营收:	$50.70M
毛利润:	$42.60M (84.02 %)
EPS:	$0.400

FY	2022
营收:	$0
毛利润:	$-4.05M (0.00 %)
EPS:	$-5.49

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.13

Financial Reports:

No articles found.

Krystal Biotech Inc

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.